Intestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan

Journal of Controlled Release

Volumn 162, Issue 3, 2012, Pages 568-574

  Mazzaferro, Silvia ^a   Bouchemal, Kawthar ^a   Skanji, Rym ^a   Gueutin, Claire ^a   Chacun, Hélène ^a   Ponchel, Gilles ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Docetaxel; Intestinal permeability; Mucoadhesion; Nanoparticles; Poly(isobutylcyanoacrylate); Thiolated chitosan

Indexed keywords

ANIONIC EMULSION POLYMERIZATION; CONTROL SOLUTIONS; DOCETAXEL; ENCAPSULATION EFFICIENCY; IN-VITRO; INCLUSION COMPLEX; INTESTINAL MEDIUM; INTESTINAL MEMBRANES; ISOBUTYLCYANOACRYLATE; MUCOADHESION; PERMEATION ENHANCEMENT; POSITIVELY CHARGED; THIOLATED CHITOSAN;

CHITOSAN; ENCAPSULATION; ETHANOL; POLYACRYLATES;

NANOPARTICLES;

ALCOHOL; BUCRILATE; CHITOSAN; DOCETAXEL; METHYL BETA CYCLODEXTRIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CHITOSAN; CYANOACRYLATES; INTESTINAL ABSORPTION; JEJUNUM; MALE; NANOPARTICLES; PANCREATIN; PERMEABILITY; RATS; RATS, WISTAR; TAXOIDS;

EID: 84865597139     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.08.005     Document Type: Article

References (30)

1. B. Nuijen, M. Bouma, J.H.M. Schellens, and J.H. Beijnen Progress in the development of alternative pharmaceutical formulations of taxanes Invest. New Drugs 19 2 2001 143 153
2. S. Mazzaferro, K. Bouchemal, G. Ponchel. Oral delivery of anti-cancer drugs I: General considerations, Drug. Discov. Today, http://dx.doi.org/10.1016/ j.drudis.2012.08.004.
3. H.A. Bardelmeijer, M. Ouwehand, T. Buckle, M.T. Huisman, J.H.M. Schellens, J.H. Beijnen, and O. van Tellingen Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir Cancer Res. 62 21 2002 6158 6164
4. S. Mazzaferro, K. Bouchemal, J.-F. Gallard, B.I. Iorga, M. Cheron, C. Gueutin, C. Steinmesse, and G. Ponchel Bivalent sequential binding of docetaxel to methyl-ß-cyclodextrin Int. J. Pharm. 416 1 2011 171 180
5. M.M. Malingré, D.J. Richel, J.H. Beijnen, H. Rosing, F.J. Koopman, W.W. Ten Bokkel Huinink, M.E. Schot, and J.H.M. Schellens Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel J. Clin. Oncol. 19 4 2001 1160 1166
6. R.L. Oostendorp, A. Huitema, H. Rosing, R.S. Jansen, R. Ter Heine, M. Keessen, J.H. Beijnen, and J.H.M. Schellens Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors Clin. Cancer Res. 15 12 2009 4228 4233
7. J.J. Moes, S.L.W. Koolen, A.D.R. Huitema, J.H.M. Schellens, J.H. Beijnen, and B. Nuijen Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) Int. J. Pharm. 420 2 2011 244 250
8. Y.-M. Yin, F.-D. Cui, C.-F. Mu, M.-K. Choi, J.S. Kim, S.-J. Chung, C.-K. Shim, and D.-D. Kim Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation J. Control. Release 140 2 2009 86 94
9. E. Lee, H. Kim, I.-H. Lee, and S. Jon In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration J. Control. Release 140 2 2009 79 85
10. B. Petit, K. Bouchemal, C. Vauthier, M. Djabourov, and G. Ponchel The counterbalanced effect of size and surface properties of chitosan-coated poly(isobutylcyanoacrylate) nanoparticle on mucoadhesion due to pluronic F68 addition Pharm. Res. 29 2012 943 952
11. I. Bravo-Osuna, C. Vauthier, A. Farabollini, G.F. Palmieri, and G. Ponchel Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles Biomaterials 28 13 2007 2233 2243
12. S. Mazzaferro, K. Bouchemal, A. Maksimenko, R. Skanji, P. Opolon, G. Ponchel, Reduced intestinal toxicity of docetaxel into mucoadhesive nanoparticles, in mouse xenograft model. J. Colloid. Sci. Biotechnol. (in press).
13. M. Werle, and M. Hoffer Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine J. Control. Release 111 1-2 2006 41 46
14. I. Bravo-Osuna, T. Schmitz, A. Bernkop-Schnürch, C. Vauthier, and G. Ponchel Elaboration and characterization of thiolated chitosan-coated acrylic nanoparticles Int. J. Pharm. 316 1-2 2006 170 175
15. K. Bouchemal, G. Ponchel, S. Mazzaferro, V.-H. Campos-requena, C. Gueutin, G.-F. Palmieri, and C. Vauthier A new approach to determine loading efficiency of Leu-enkephalin in poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan J. Drug Del. Sci. Technol. 18 6 2008 392 397
16. A. Monza da Silveira, G. Ponchel, F. Puisieux, and D. Duchêne Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs Pharm. Res. 15 7 1998 1051 1055
17. A. Monza Da Silveira, G. Ponchel, D. Duchene, P. Couvreur, F. Puisieux, Nanoparticles comprising polyisobutylcyanocrilate and cyclodextrins, WO Patent, 1999.
18. M. Aboubakar, P. Couvreur, H. Pinto-Alphandary, B. Gouritin, B. Lacour, R. Farinotti, F. Puisieux, and C. Vauthier Insulin loaded nanocapsules for oral administration: in vitro and in vivo investigation Drug Dev. Res. 49 2000 109 117
19. M. Agüeros, L. Ruiz-Gatón, C. Vauthier, K. Bouchemal, S. Espuelas, G. Ponchel, and J. Irache Combined hydroxypropyl-[beta]-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel Eur. J. Pharm. Sci. 38 4 2009 405 413
20. A. Dembri, D. Duchêne, and G. Ponchel The intestinal mucus protects poly(isobutylcyanoacrylate) nanoparticles from enzymatic degradation STP Pharm. Sci. 11 2 2001 175 180
21. H. Lennernäs Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Deliv. Rev. 59 11 2007 1103 1120
22. W. Ke, Y. Zhao, R. Huang, C. Jiang, and Y. Pei Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system J. Pharm. Sci. 97 6 2008 2208 2216
23. M.V.S. Varma, and R. Panchagnula Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur. J. Pharm. Sci. 25 4-5 2005 445 453
24. I.E.L.M. Kuppens, T.M. Bosch, M.J. Maanen, H. Rosing, A. Fitzpatrick, J.H. Beijnen, and J.H.M. Schellens Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) Cancer Chemother. Pharm. 55 1 2005 72 78
25. C. Kruijtzer, J. Beijnen, and J. Schellens Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview Oncologist 7 6 2002 516 530
26. P. Mardones, D. Andrinolo, A. Csendes, and N. Lagos Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique Toxicon 44 5 2004 521 528
27. S. Tilloy, V. Monnaert, L. Fenart, H. Bricout, R. Cecchelli, and E. Monflier Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier Bioorg. Med. Chem. Lett. 16 2006 2154 2157
28. P.Y. Grosse, F. Bressolle, and F. Pinguet In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin Eur. J. Cancer 34 1 1998 168 174
29. M. Werle Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery J. Pharm. Sci. 97 2007 60 70
30. F. Föger, H. Hoyer, K. Kafedjiiski, M. Thaurer, and A. Bernkop-Schnürch In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein Biomaterials 27 34 2006 5855 5860